Early aggressive DMARD therapy: The key to slowing disease progression in rheumatoid arthritis

Scandinavian Journal of Rheumatology, Supplement

Volumn 28, Issue 112, 1999, Pages 3-7

  Hochberg, M C ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Combination therapy; Drug therapy; Outcomes; Prognostic indicators; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOSPORIN; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; BIOLOGICAL MARKER;

AGE; AUTOIMMUNE DISEASE; DEATH; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; JOINT DESTRUCTION; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SHORT SURVEY; BLOOD; DAILY LIFE ACTIVITY; FEMALE; MALE; REVIEW;

ACTIVITIES OF DAILY LIVING; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PROGNOSIS;

EID: 0033397208     PISSN: 03013847     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097499750042227     Document Type: Short Survey

References (13)

1. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis. A 19-year study of radiographic progression. Arthritis Rheum 1998;41:1571-82.
2. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991;18:1298-306.
3. Wolfe F, Hawley DJ. The long-term outcomes of rheumatoid arthritis: work disability: a prospective 18-year study of 823 patients. J Rheumatol 1998;25:2108-17.
4. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
5. Doeglas D, Suurmeijer T, Krol B, Sanderman R, van Leeuwen M, Rijswijk M. Work disability in early rheumatoid arthritis. Ann Rheum Dis 1995;54:55-60.
6. Mau W, Bornmann M, Weber H, Weidemann HF, Hecker H, Raspe HH. Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: results of a tree structured analysis using RECPAM. Br J Rheumatol 1996;35:652-9.
7. Makisara GL, Makisara P. Prognosis of functional capacity and work capacity in rheumatoid arthritis. Clin Rheumatol 1982;1:117-25.
8. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Loew-Friedrich I, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-66.
9. Forre Ø. Norwegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994;37:1506-12.
10. Hannonen P, Möttönen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501-9.
11. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch Int Med 1999:159: in press.
12. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
13. Boers M, Verhoeven AC, Markusse HM, van de Laar MAF, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone. methotrexate and sulphasalazine with sulphasalazine alone in earls rheumatoid arthritis. Lancet 1997;350:309-18.